MindMaze Therapeutics: Corporate Update and Investor Presentation

MindMaze Therapeutics Holding SA, a company focused on digital treatments for neurological diseases, has provided a corporate update and published its investor presentation for March 2026. CEO Alexandre Capet emphasized the company's ongoing efforts to expand access to neurotherapies and to deliver clinical benefits to patients.

In the United States, MindMaze is in discussions with provider groups to broaden platform adoption, using compelling evidence and a unique reimbursement code. The company is bolstering its U.S. organization by recruiting field specialists and consolidating medico-economic evidence.

In Europe, MindMaze is working on reimbursement-focused initiatives, including new studies like SwissNeuroRehab and React-AVC, to demonstrate clinical and socio-economic benefits compared to standard care models. Over 100 hospitals in Europe are already using its solutions.

The company is also optimizing its organization through a strategic integration plan, evaluating alternatives for non-core assets while enhancing capital efficiency. Changes in the Board of Directors are underway, with new proposals expected at the next shareholder meeting.